CONMED Co. Logo
US2074101013
886793
CNMD

CONMED Co.

Se i Terminal

Prognose

Analytikernes gennemsnitlige kursmål er 37,98 € (-10,42 %). Medianen er 35,54 € (-16,18 %).

Køb
  7
Behold
  13
Sælg
  1

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • CONMED: growth accelerates due to AirSeal, BioBrace and international expansion

    CONMED reports at the Wells Fargo conference an accelerated growth dynamic and expects 2026 revenue growth of 5–6% with a pickup to 6–8% in the second half of the year. Drivers are the products AirSeal, BioBrace and Buffalo Filter as well as increasing internationalization, which now accounts for 45% of revenue. Management sees margin expansion of 50–100 basis points, improved free cash flow conversion through inventory and working-capital optimization, and plans selective acquisitions while prioritizing debt reduction. » Mere på de.investing.com


  • CONMED Corporation considers sale – shares jump more than 8% after Bloomberg report

    CONMED Corporation’s shares rose more than 8 percent in Friday after-hours trading after Bloomberg reported that the medical-technology company was weighing a possible sale. According to the report, CONMED is evaluating its options after takeover interest was expressed. » Mere på de.investing.com


  • CONMED appoints John E. Gallagher as CFO effective July 15, 2026

    CONMED has appointed John E. Gallagher as its new chief financial officer; he will assume the role on July 15, 2026. Gallagher succeeds Todd Garner, who will remain with the company in an advisory capacity until November 2, 2026. Gallagher brings about 30 years of financial and industry experience, most recently as CFO of Certara and previously of Cue Health, along with extensive leadership experience at Becton, Dickinson & Co. » Mere på de.investing.com


  • Conmed stock falls to 52-week low at $32.1

    Conmed shares hit a 52-week low of $32.1 and are down about 37.92% year-to-date. Despite the price decline, the company is rated as having a "GOOD" financial score and is valued at a P/E ratio of 18.27; InvestingPro classifies the stock as significantly undervalued. Conmed beat Q1 2026 analyst expectations for EPS ($0.89 vs. $0.82) and revenue ($317 million) and secured a $450 million term-loan facility to repay convertible bonds. Management repurchased shares, and the board will be expanded on July 1, 2026, with the additions of Celine Martin and Jeff Mirviss. » Mere på de.investing.com


  • CONMED raises organic growth, gastroenterology exit weighs on revenue

    CONMED beat adjusted EPS expectations for Q1 2026 with $0.89 and reported total revenue of $317.0 million, with reported growth pressured by the withdrawal from the gastroenterology business and currency effects. Adjusted for the divestiture of the GI business, organic growth at constant exchange rates was 2.1%, while the divestiture caused a 5.1 percentage-point headwind. Orthopedic surgery showed strong momentum with $147.7 million and +4.5% currency‑adjusted growth, while domestic revenue declined. CONMED raised its organic full-year growth outlook to 5.0–6.5%, kept the adjusted EPS target at $4.30–4.45, and emphasized portfolio focus and supply‑chain transformation; the stock nevertheless fell in after‑hours trading. » Mere på de.investing.com

I 2025 har CONMED Co. allerede udloddet 0,71 € i udbytte. Den seneste udlodning fandt sted i oktober 2025.

Virksomhedstal

I det seneste kvartal havde CONMED Co. en omsætning på 296,25 mio. € og et nettoresultat på 17,48 mio. €

(EUR) september 2026
YoY
Omsætning 296,25 mio. 2,68 %
Bruttofortjeneste 166,99 mio. 24,06 %
Nettoresultat 17,48 mio. 617,37 %
EBITDA 49,73 mio. 91,42 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
1,26 mia. €
Antal aktier
29,8 mio.
Højeste/laveste i 52 uger
49,94 € - 28,65 €
Udbytte Nej
Beta
0,90
P/E (PE Ratio)
19,24
PEG (PEG Ratio)
1,10
K/I (PB Ratio)
1,31
P/S (PS Ratio)
1,01

Virksomhedsprofil

CONMED Corporation, et medicinteknologisk selskab, udvikler, fremstiller og sælger kirurgiske instrumenter og tilhørende udstyr til kirurgiske indgreb over hele verden. Selskabet tilbyder ortopædiske kirurgiske produkter, herunder TruShot med Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors og PopLok Knotless Suture Anchors, som giver ortopædkirurger unikke kliniske løsninger til reparation af bløddelsskader, samt understøttende produkter, der gør det muligt for kirurger at udføre minimalt invasive sportsmedicinske operationer. Selskabet markedsfører ortopædiske kirurgiske produkter under mærkerne Hall, CONMED Linvatec, Concept og Shutt. Det tilbyder også produkter til generel kirurgi, såsom udstyr til klinisk insufflation, røgudsugning, elektrokirurgi og endomekaniske produkter; samt endoskopiske teknologier, herunder diagnostiske og terapeutiske produkter til brug i gastroenterologiske indgreb og produkter til behandling af sygdomme i galdevejene, samt kardiale monitoreringsprodukter bestående af EKG- og EEG-elektroder og defibrillationspuder til hjertet. Selskabet markedsfører sine produkter direkte til hospitaler, kirurgiske centre og andre sundhedsinstitutioner samt gennem specialiserede medicinske distributører. CONMED Corporation blev stiftet i 1970 og har hovedkvarter i Largo, Florida.

Navn
CONMED Co.
CEO
Patrick J. Beyer
Hjemsted Largo, fl
USA
Websted
Sektor
Sundhed
Branche
Sundhedsteknologi
Børsnotering
23.07.1987
Medarbejdere 3.900

Tickersymboler

Børs Symbol
NYSE
CNMD
Frankfurt
EC8.F
DĂĽsseldorf
EC8.DU
SIX
EC8.SW
MĂĽnchen
EC8.MU
🍪

Parqet  bruger cookies. Læs mere